LeaderShift Blog
LeaderShift Blog
-
Heather Hunt is appointed Principal at The Hunt Group1/1/2010
Heather Hunt is appointed Principal at The Hunt Group
Heather Hunt has been appointed Principal at Hunt Executive Search, Inc. Charlotte office, the largest Charlotte area Retained Executive Search firm. Heather began her career as an Associate after graduated from UNC Chapel Hill Kenan Flagler School of Business and has been a Search Consultant in both the Consumer Goods and Life Sciences Global practices for 5 years. Congratulations on your outstanding accomplishment Heather!Sanofi-Aventis to Buy Chattem, Maker of Icy Hot, for About $1.9 Billion12/21/2009
Sanofi-Aventis to Buy Chattem, Maker of Icy Hot, for About $1.9 Billion
Sanofi-Aventis to Buy Chattem, Maker of Icy Hot, for About $1.9 Billion
Sanofi-aventis and Chattem, Inc. announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire 100 percent of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion. The transaction will create the world's fifth-largest consumer healthcare company measured by product revenues by combining Chattem's position as a leading U.S. consumer healthcare company with sanofi-aventis' strong international presence in the sector.Over-the-counter ("OTC") and consumer brands are core growth platforms identified in sanofi-aventis' broader strategy for achieving sustainable growth. Although the Group will generate around 1.4 billion euros worldwide in OTC sales in 2009, it has thus far not been directly present in the United States.Chattem is approximately 130 years old and is a leading manufacturer and marketer of branded consumer healthcare products, toiletries and dietary supplements across niche market segments in the United States. Chattem has regularly demonstrated its ability to sustain regular growth, both in terms of sales and profit, through the development of its own brands and the successful integration of acquired products. Chattem's well known brands include Gold Bond®, Icy Hot®, ACT®, Cortizone-10®, Selsun Blue® and Unisom®.Sanofi-aventis also announced today that it will seek to convert its antihistamine brand known as Allegra® (fexofenadine HCl) in the United States from a prescription medicine to an OTC product. Allegra® is a well recognized brand name with both physicians and consumers. Upon Allegra®'s conversion, Chattem will assume responsibility for the Allegra® brand as part of becoming the platform for sanofi-aventis' U.S. OTC and consumer healthcare business."The acquisition of Chattem will be a significant milestone in sanofi-aventis' transformation strategy and will provide us with the ideal platform in the U.S. consumer healthcare market, which represents 25 percent of the current worldwide opportunity," said Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. "In addition, we believe our ability to convert prescription medicines to OTC products will be enhanced by Chattem's leading sales, marketing and distribution channels. We have great respect for Chattem's world-class management team, which has an excellent track record of sales and earnings growth based on building strong brands. With the potential access to switch products such as Allegra®, I believe this team will take Chattem to even higher levels.""This transaction offers immediate and significant value for Chattem's shareholders and important benefits to our employees, customers and community," said Zan Guerry, Chairman and Chief Executive Officer of Chattem. "I am excited to work with the sanofi-aventis team to capture the significant growth opportunities this combination creates, as highlighted by the planned launch of Allegra®. Chattem will form the base of a new consumer healthcare business in the United States for sanofi-aventis, and the headquarters, manufacturing and leadership team will continue to be based in Chattanooga."Under the terms of the agreement, sanofi-aventis will commence a tender offer for all outstanding shares of Chattem at $93.50 per share in cash. The offer price represents a 34 percent premium above the closing price of Chattem's shares on December 18, 2009 and a 44 percent premium above the average closing price of Chattem's shares during the 6 months preceding the announcement of the transaction.The tender offer is conditioned on the tender of a majority of Chattem's shares calculated on a diluted basis, as well as the receipt of certain regulatory approvals and other customary closing conditions. Following the successful completion of the tender offer, a wholly owned subsidiary of sanofi-aventis will merge with Chattem and the outstanding Chattem shares not tendered in the tender offer will be converted into the right to receive the same $ 93.50 per share in cash paid in the tender offer. The tender offer will commence in January 2010 and the companies anticipate the transaction will close in the first quarter of 2010. Chattem's Board of Directors has unanimously approved the transaction.The transaction is expected to be accretive to sanofi-aventis' earnings as early as year one. This acquisition will allow sanofi-aventis to optimize and retain the full value of the Allegra® switch to an OTC product. Also, significant revenue synergies should be obtained through the expansion of Chattem's products into geographic markets where sanofi-aventis has a strong operating presence, particularly in emerging markets.Zan Guerry and the senior leadership team of Chattem have agreed to lead sanofi-aventis' U.S. consumer health division following the close of the transaction. Additionally, sanofi-aventis is committed to Chattem's current operations and entrepreneurial spirit as it builds a sizeable presence in the U.S. consumer healthcare market. Sanofi-aventis announced it would maintain both of Chattem's existing manufacturing facilities and will continue construction on the third. The corporate brand of Chattem will also be maintained.Alberto Culver acquires Simple Health & Beauty Limited12/14/2009
Alberto Culver acquires Simple Health & Beauty Limited
Alberto Culver acquires Simple Health & Beauty Limited
Alberto Culver, whose brands include St. Ives and Noxzema, is expanding its skin care portfolio by acquiring Simple Health & Beauty Limited, a U.K.-based skin care company, from private equity fund Duke Street.The purchase price is 240 million pounds ($390 million). The deal is expected to close by the end of the year.With the acquisition, Alberto Culver will become the No. 2 manufacturer in the U.K. in skin care to complement its existing No. 2 position in hair care, the company stated."Simple is a brand that we have followed for a long time due to its strong, differentiated positioning in the skin care category. I've admired the tremendous job that the management team has done in growing the business and we?ll continue to leverage Simple's brand strengthen to drive future growth. This transaction reaffirms our overall focus on beauty care while moving us an important step forward in executing our strategy of expanding and strengthening our skin care portfolio," stated Alberto Culver president and CEO V. James Marino.Green Mountain to Buy Diedrich Coffee12/8/2009
Green Mountain to Buy Diedrich Coffee
Green Mountain to Buy Diedrich Coffee
Diedrich Coffee Inc. Tuesday said it agreed to be acquired by Green Mountain Coffee Roasters Inc., a deal which follows more than a monthlong bidding war for the single-serve coffee brand.
Under the deal, Green Mountain will acquire all of the outstanding shares of Diedrich for $35 in cash per share, or about $290 million.
Diedrich Coffee said it terminated a merger agreement with Peet's Coffee & Tea Inc. and that Green Mountain has paid Peet's the $8.517 million termination fee on behalf of Diedrich Coffee.
Peet's, which sells premium coffee and teas, was pursuing Diedrich to try to get a foothold into the fast-growing single-serve coffee market in the form of K-Cups, plastic pods used in Keurig coffee machines. The machines have exploded in popularity in recent years, as they offer a convenient way to brew a cup of coffee from a choice of flavors. Over the last year, Keurig shipped 1.6 billion K-Cup portion packs, up 63% from last year.
The Keurig technology is owned by Green Mountain, which appears to want to bring more of the brands licensed to sell K-Cups under its wings. Green Mountain recently bought a separate coffee brand, Timothy's Coffee of the World Inc., for $157 million.
Peet's had raised its bid to $32.50, but that offer expired, leaving the bid at $26. Peet's said late Monday that it wouldn't raise its offer. Peet's Chief Executive Patrick O'Dea said that Peet's deal could close in weeks while antitrust issues raised by a deal with Green Mountain remains subject to review.
However, analysts have said risk of the Green Mountain deal violating antitrust laws is minimal, because consumers have several other options for in-home coffee brewing besides the Keurig single-cup brewers Green Mountain and Diedrich provide.
Peet's failed to submit a new proposal to Diedrich Coffee by the Monday deadline, Diedrich Coffee said.
P&G Nears Deal for Sara Lee Unit12/8/2009
P&G Nears Deal for Sara Lee Unit
P&G Nears Deal for Sara Lee Unit
Procter & Gamble. is close to a deal to buy Sara Lee.'s European air-freshener business, after fending off a challenge from S.C. Johnson & Son Inc., according to people familiar with the matter.
A deal is likely to be signed in the next few days, they said. While the price is not clear, people familiar with the matter have said in the past that the business could fetch as much as $700 million.
The sale of the Sara Lee operation, which includes the Ambi Pur brand and has roughly $500 million of global annual sales, would bring Sara Lee a step closer to its nearly yearlong goal of selling its international household and personal-care products businesses.
Sara Lee had hoped to sell the businesses as one, but has been forced to sell them in pieces instead. In September, Sara Lee reached a deal to sell the personal-care unit to Anglo-Dutch consumer-products company Unilever NV for about $1.9 billion.
The air-freshener deal would leave Sara Lee with two chunks of the international businesses left to sell: Kiwi shoe polish and an insecticide maker. Closely held S.C. Johnson, which was told last week that its bid was rejected according to the people, may still buy other parts of the Sara Lee business.
Sara Lee, which officially put the international division up for sale earlier this year, declined to comment, as did P&G. An official for S.C. Johnson, which is based in Racine, Wis., couldn't immediately be reached.
Celgene acquires Gloucester Pharmaceuticals12/7/2009
Celgene acquires Gloucester Pharmaceuticals
Celgene acquires Gloucester Pharmaceuticals
Celgene made another move to strengthen its expanding pipeline of cancer medicines Monday with the acquisition of Gloucester Pharmaceuticals, a private biotech company with a new drug for treating lymphoma.The deal calls for Celgene, based in Summit, to pay $340 million in cash for the six-year-old Massachusetts-based biotech and to make additional payments of $300 million for future U.S. and international regulatory milestones."This acquisition makes sense on multiple fronts,’’ Wells Fargo Securities analyst Aaron Reames said in a research note. "We view it as a smart use of Celgene’s war chest of cash.’’Gloucester, which is based in Cambridge, Mass., received federal regulatory approval last month to begin selling Istodax, a new type of drug for treating T-cell lymphoma.Celgene has grown into one of the nation’s largest biotechnology companies through the development of two key cancer drugs and a recent series of acquisitions. Last year, the company acquired Pharmion to bolster its product pipeline as well as its ability to take new medicines to market.Reames said one of the benefits of the acquisition is the timing of Isotodax's ramp up. Isotodax’s revenues would ramp up, he said, over the next two years to help offset the decline in sales of Vidaza, a drug Celgene gained from Pharmion, expected to occur in 2011 when the drug’s U.S. patent expires.Smucker brothers named MarketWatch CEO of the Year12/3/2009
Smucker brothers named MarketWatch CEO of the Year
They are still known as "the boys" around J.M. Smucker Co., the 112-year-old maker of fruit jams and peanut butter.
Brothers Tim and Richard Smucker grew up around the family business, listening to their dad talk shop at the breakfast table, and as teenagers loading trucks and mopping jelly off factory floors. As they grew older, taking jobs in the finance and marketing departments, they eventually would form an unusual partnership that has elevated the company from small-town beginnings in Orrville, Ohio, to power player in the food world.Several large deals were done on the brothers' watch in the past six years. But the $3.7 billion purchase of the Folgers coffee brand from Buckeye State neighbor Procter & Gamble stands out from the rest.It couldn't have been timed better. Closed a year ago, the deal put the first billion-dollar franchise into Smucker's pantry, adding coffee to a lineup that was stocked with names like Hungry Jack pancake mixes, Pillsbury cake icing, and Jif peanut butter.Mergers often fail to reward investors as promised. Under the brothers, however, J.M. Smucker /quotes/comstock/13*!sjm/quotes/nls/sjm (SJM 58.98, -0.52, -0.87%) delivered this year with Folgers, investors and analysts say. Folgers sales have grown by a percentage in the "high single digits" and topped most expectations. Growth kicked in last spring, when Folgers sales surged after a flat, and at times declining, year. In the past two quarters, Folgers volumes have risen by 9% and 5%, respectively."We have to give it high marks," Chuck Cerankosky, a NorthCoast Research analyst, said of the performance.By turning their biggest acquisition yet into a success, delivering to shareholders sweet gains in a sour climate, and stressing ethics in their oft-praised workplace, the Smucker brothers are the co-winners of MarketWatch's CEO of the Year for 2009.They've been spooning out good results all year long. And Smucker gave investors more to nibble on recently when it lifted the long-term operating-margin forecast for the Folgers business by two percentage points to 30%. For the country's legions of cash-strapped consumers, Smucker cut the price of the brand's familiar red canisters of coffee.For brand-name-packaged-food makers during the recession, volume growth has been hard to come by, as retailers have cut inventories and Americans have pulled the purse strings ever tighter.Having Folgers in house has only strengthened Smucker's ability to respond, as cross promotions have spurred demand for Hungry Jack pancake mixes and syrups, the company's namesake jams, Pillsbury bake mixes and Jif.Not counting the Folgers side of the house, Smucker also achieved modest volume-growth pickups this year in the second and third quarters. Hungry Jack, Jif, Pillsbury, and Crisco have led the way. The struggle for growth at other food companies, including the likes of H.J. Heinz, Hormel, Sara Lee and Kraft, has been less successful.With the boys presiding, Smucker sales have grown fivefold through acquisitions over the past six years, thrusting the Orrville food purveyor into the No. 1 market-share position in 10 different categories in the central aisles of America's grocery stores.When it came to getting their hands on Folgers, the brothers had their work cut out for them in persuading P&G /quotes/comstock/13*!pg/quotes/nls/pg (PG 61.88, -0.59, -0.94%) to sell Smucker a business it had long coveted to complement its breakfast and dessert offerings.P&G had publicly stated its intention to make Folgers a stand-alone outfit and was working with its bankers to achieve that goal. It took four months for the Smuckers to sell P&G on the argument that their proposition was a more compelling one. After that, they had to win back investors who'd punished Smucker in the weeks after the deal was unveiled.Once the acquisition was completed, however, the brothers moved swiftly to cash in on the Folgers name.Smucker brothers named MarketWatch CEO of the Year
Tim and Richard Smucker, the brothers who helm the 112-year-old spread company that bears their name, are sharing the honor of being MarketWatch CEO of the Year in 2009. They are recognized for several successful deals, particularly the $3.7 billion purchase of the Folgers coffee brand from Procter & Gamble in 2008.
Novartis, Incyte in potential $1.3B drug-licensing deal11/25/2009
Novartis, Incyte in potential $1.3B drug-licensing deal
Novartis, Incyte in potential $1.3B drug-licensing deal
Incyte licenses myelofibrosis and cancer treatments to Novartis in deal that could top $1.3BDrug developer Incyte Corp. on Wednesday licensed two potential drugs, including a treatment for myelofibrosis, to Swiss drugmaker Novartis AG In a deal that could be worth more than $1.3 billion.Novartis and Incyte will team up to develop and market INCB18424, which is currently in late stage testing as a treatment for the bone marrow disease myelofibrosis. Incyte will have the U.S. rights to the drug.Novartis will have full worldwide rights to INCB28060, an experimental cancer drug that is about to go into human testing.Incyte, based in Wilmington, Del., is getting an upfront payment of $150 million, along with a $60 million milestone payment for the start of late stage testing of INCB18424 in Europe. Novartis could make about $1.1 billion in other payments if the drug reaches sales and development milestones.Incyte also will get royalty payments of more than 10 percent on sales.Myelofibrosis can cause bone marrow failure, spleen swelling, and other health problems.Novartis will have the right to develop oral versions of INCB19424 for blood diseases and cancers. Incyte is testing a topical version of the drug as a treatment for psoriasis and rheumatoid arthritis.Novartis will also pay royalties on sales of INCB28060 if that drug is approved.In morning trading, Incyte stock rose 56 cents, or 7.3 percent, to $8.28. The stock earlier traded at $8.64, eclipsing a 52-week high of $8.32 set Nov. 17.Shares of Novartis rose 44 cents to $55.74. They earlier reached a 52-week high of $55.87, topping a previous peak of $55.36 set Tuesday.Blackstone’s Pinnacle Foods to Acquire Birds Eye in $1.3 Billion Deal11/19/2009
Blackstone’s Pinnacle Foods to Acquire Birds Eye in $1.3 Billion Deal
Blackstone’s Pinnacle Foods to Acquire Birds Eye in $1.3 Billion Deal
Birds Eye Foods, the largest frozen-vegetable company in the U.S., is expected to be acquired for more than $1.3 billion by Pinnacle Brands Corp., according to people familiar with the matter.
The all-cash deal is likely to be announced as soon as Thursday, said these people. Pinnacle, owned by New York's Blackstone Group, is one of the country's largest packaged-food companies with well-known consumer brands such as Duncan Hines baking mixes and Swanson frozen dinners.
The Rochester, New York-based Birds Eye, known for its branded frozen vegetables and frozen meals, is majority owned by the private-equity firm Vestar Capital Partners. It is also 40% owned by Pro-Fac, a 48-year-old New York agricultural cooperative. Birds Eye carries about $700 million in long-term debt.
Acquired by Vestar in 2002, Birds Eye is sold in most of the country's largest grocery stores, including Wal-Mart, Kroger and Safeway. Birds Eye, which has about 1700 full-time employees, has a dominant niche in warehouses and distribution centers across the Midwest in states including Michigan, Minnesota and Wisconsin.
Representatives for Blackstone and Birds Eye did not reply to phone calls and emails seeking comment.
The New Jersey-based Pinnacle was acquired by Blackstone in 2007 for $2.2 billion. It houses names common with consumers such as Vlasic pickles, Mrs. Butterworth pancake syrup and Open Pit barbeque sauce.
For the first nine months of the year, Pinnacle frozen foods with about 25 percent of the frozen-vegetable market in the United States. It has
reported net earnings of $10.8 million on sales of $1.23 billion.
The all-cash deal is yet another sign that private-equity funds have become more willing to make acquisitions after a tumultuous two-year period. Many private-equity funds are also eager to sell off businesses, having delivered few returns during the freeze in the credit and merger markets.
The purchase may also be another signal that lenders are willing to lend at higher leverage levels. In early November IMS Health agreed to a $4 billion private-equity leveraged buyout at five times earnings, a higher level than had been considered reasonable this year.
S.C. Johnson Vies with P&G for Sara Lee Unit11/17/2009
S.C. Johnson Vies with P&G for Sara Lee Unit
S.C. Johnson Vies with P&G for Sara Lee Unit
S.C. Johnson & Son Inc. has joined the bidding for Sara Lee Corp.'s air-freshener business, according to people familiar with the matter, pitting it against consumer-products giant Procter & Gamble Co.A deal for the unit, which could fetch more than $700 million, could still be weeks away. S.C. Johnson is also interested in other parts of Sara Lee's international household-care business, which includes insecticides and Kiwi shoe polish, the people said. Sara Lee declined to comment, as did S.C. Johnson, of Racine, Wis.The emergence of competition for P&G, whose interest in the air-care business surfaced last month, could be another step toward Sara Lee's goal of selling its international household and personal-care business. The company officially put the operations on the auction block in March and hired Goldman company Unilever NV for about $1.9 billion.The protracted auction had led to speculation that Sara Lee would either have to accept a lower price for the assets than it hoped or pull some of them off the market.A person briefed on the matter said that a number of possible bidders are still in the running for other parts of the household-products business and that all of the operations could be worth more than $1 billion. That could bring total proceeds from the household and personal-care sale to more than $3 billion—higher than some analysts estimated the businesses would fetch when they were first put up for sale.Sara Lee had originally hoped to sell the entire household and personal-care business to a single buyer but soon had to settle for a piecemeal sale.Ambi Pur, the flagship brand of Sara Lee's air-freshener business, had about $470 million in sales last year. Putting it together with closely held S.C. Johnson's Glade air freshener, which has a big presence in Europe, could yield big benefits, one of the people said. It is unclear whether such a combination would raise antitrust concerns.In addition to products such as Crest toothpaste and Tide detergent, Cincinnati-based P&G makes the odor remover Febreze.Sara Lee Chief Executive Brenda Barnes has reshaped the Downers Grove, Ill., company since she took the helm in 2005, when it was a sprawling consumer-products giant. The sale of the international brands is part of a four-year effort at the company to slim down. Shedding the household and personal-care brands would reshape the company into a conglomerate mostly focused on food and beverages.Sara Lee shares rose 20 cents to $12.18 in afternoon trading on the New York Stock Exchange Tuesday, giving the company a market value of about $8.5 billion. After a decade-long slide, the shares have gained roughly 75% since March.
Displaying Records 171 to 180 of 602
<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14
15 16 17 [18] 19 20 21 22 23 24 25 26 27 28 29
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
60 61 Next >>Boutique executive search services with best in class global network, contacts and market mastery.
Deeply connected and engaged personal service approach, long-term investment in client community and 25 year history of strong relations with both Multi-National leaders and Private Equity partners.
Copyright © 2022 TalentGate All Right Reserved. - Privacy Policy - Sitemap